Evidence map›Paper›PMID 38585724›Full record

ArticlebioRxiv : the preprint server for biology2024

Pharmacogenomic synthetic lethal screens reveal hidden vulnerabilities and new therapeutic approaches for treatment of NF1-associated tumors.

Kyle B Williams, Alex T Larsson, Bryant J Keller, Katherine E Chaney, Rory L Williams, Minu M Bhunia, Garrett M Draper, Tyler A Jubenville, Wendy A Hudson, Christopher L Moertel and 2 more

Open access · greenAbstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 4 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Kyle B WilliamsDepartment of Pediatrics, Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA.ORCID 0000-0003-4333-9111
Alex T LarssonDepartment of Pediatrics, Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA.ORCID 0000-0002-1350-8271
Bryant J KellerDepartment of Pediatrics, Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA.
Katherine E ChaneyDivision of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital, Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, 45229-0713, USA.
Rory L WilliamsDepartment of Pediatrics, Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA.ORCID 0000-0003-2605-5790
Minu M BhuniaDepartment of Pediatrics, Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA.ORCID 0000-0002-2849-1572
Garrett M DraperDepartment of Pediatrics, Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA.ORCID 0000-0002-4972-8233
Tyler A JubenvilleDepartment of Pediatrics, Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA.ORCID 0009-0003-9578-4847
Wendy A HudsonDepartment of Pediatrics, Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA.
Christopher L MoertelDepartment of Pediatrics, Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA.ORCID 0000-0002-5474-588X
Nancy RatnerDivision of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital, Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, 45229-0713, USA.ORCID 0000-0001-5030-9354
David A LargaespadaDepartment of Pediatrics, Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA.ORCID 0000-0002-3183-0491
University of Minnesota System · USCincinnati Children's Hospital Medical Center · USUniversity of Minnesota · US

Funding

Uncovering treatment targets for peripheral nerve sheath tumor progression in NF1R01NS115438 · NINDS · UNIVERSITY OF MINNESOTA · PI LARGAESPADA, DAVID ANDREW, RATNER, NANCY · 2020 to 2024
$2.9M
Disordered Regulation of Wnt/beta-catenin Signaling in MPNST Development and MaintenanceR01NS086219 · NINDS · UNIVERSITY OF MINNESOTA · PI LARGAESPADA, DAVID ANDREW, RATNER, NANCY · 2014 to 2018
$2.4M
NINDS NIH HHS R01 NS086219NINDS NIH HHS R01 NS115438
6 · The paper itself

Abstract

Neurofibromatosis Type 1 (NF1) is a common cancer predisposition syndrome, caused by heterozygous loss of function mutations in the tumor suppressor gene

Identifiers

PMID38585724
PMCPMC10996510
OpenAlexW4393196440

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.